HYDERABAD: Aurobindo Pharma Limited (APL) on Saturday announced that, by and through its wholly owned step-down subsidiary Agile Pharma BV, it had entered into a binding agreement to acquire Portugal-based Generis Farmaceutica SA and its subsidiaries for Euro 135 million (about Rs 970 crore), including net working capital of Euro 21.7 million.
The transaction includes Generis production facility at Amadora in Portugal which has an annual capacity of 1.2 billion tablets, capsules and sachets.
Aurobindo stated that the acquisition catapults APL group to numero uno position both in value and volume in the generics market of Portugal. APL already has a presence in Portugal through its subsidiaries Aurovitas Unipessoal LDA and Aurobindo Pharma (Portugal) Unipessoal Limitada.
Currently, Aurobindo said, Generis is the "most sold" pharmaceutical brand in Portugal. The group is ranked second by value in the Potuguese generic pharma market.
